Your Best Stock
Stocks Biotechnology REGN

Regeneron Pharmaceuticals REGN

US equityMarket cap rank #199BiotechnologyInfectious Disease
$791.33
−$10.50 (-1.31%)
Market open · Sep 24, 1:10 pm ET
After hours $801.82 0.00%
Open$801.59
Prev close$801.82
Day range$789.41 – $807.21
Volume246.9K
Market cap$81.47B
P/E (TTM)19.6
Dividend yield0.46%
Founded1988
CEODr. Leonard S. Schleifer,M.D.,PhD
Employees15,410
HeadquartersTarrytown, United States of America

About

Regeneron is a biotech company best known for the eye drug Eylea and the inflammation drug Dupixent, developed with Sanofi.

What tends to move the stock

Dupixent growth, competition from Eylea biosimilars and the oncology pipeline decide the outlook.

Sectors & themes

Scroll to Top